GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...

Please provide your email address to receive an email when new articles are posted on . Traumatic optic nerve head avulsion and traumatic optic neuropathy are serious and can be visually devastating.

A Prescription Drug User Fee Act target date of February 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

Please provide your email address to receive an email when new articles are posted on . “Population-based detailed information about the prevalences of all three types of optic nerve damage and their ...

The FDA agreed that the design of a Phase 3 trial testing privosegtor in optic neuritis could support a future approval ...

The use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is not associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) in patients with ...

When a study published in JAMA Ophthalmology reported that semaglutide users developed a rare form of sudden vision loss at ...

A Medicare cohort study of nearly 4 million older patients with type 2 diabetes found 2 in 1000 developed nonarteritic anterior ischemic optic neuropathy (NAION) over a period of more than 3 years.

A new observational study on Wednesday reported for the first time a potential link between Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy and an eye condition that can cause vision loss. After hearing ...